The molecular and cellular origin of human prostate cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 6, 2016, Pages 1238-1260

  Packer, John R ^a   Maitland, Norman J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; TELOMERASE;

BASEMENT MEMBRANE; CANCER CELL; CANCER INCIDENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CLONAL EVOLUTION; DNA REPAIR; GENE EXPRESSION; GLEASON SCORE; HUMAN; IMMUNOPHENOTYPING; MALE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; REVIEW; SOMATIC MUTATION; STEM CELL NICHE; STOCHASTIC MODEL; TELOMERE; BIOLOGICAL MODEL; CELL LINEAGE; CELL TRANSFORMATION; CHROMOSOME ABERRATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; HUMANS; INFLAMMATION; MALE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84962739412     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2016.02.016     Document Type: Review

References (382)

1. Cancer Research UK Prostate cancer incidence statistics (Internet, Available from:, (cited 2015 Oct 29. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-One.
2. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91(14:1194-1210. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/10413421.
3. Maitland N.J. Stem Cells in the Normal and Malignant Prostate. Prostate Cancer - Biochemistry, Molecular Biology and Genetics 2013, 3-41. Springer, New York. D.J. Tindall (Ed..
4. Frame F.M., Maitland N.J. Cancer Stem Cells, Models of Study and Implications of Therapy Resistance Mechanisms. Advances in Experimental Medicine and Biology 2011, 105-118.
5. Robinson E.J., Neal D.E., Collins A.T. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998.
6. Frame F.M., Hager S., Pellacani D., Stower M.J., Walker H.F., Burns J.E., et al. Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Exp. Cell Res. 2010, 316(19:3161-3171.
7. Blackwood J.K., Williamson S.C., Greaves L.C., Wilson L., Rigas A.C., Sandher R., et al. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J. Pathol. 2011, 225(2:181-188.
8. Grisanzio C., Signoretti S. p63 in prostate biology and pathology. J. Cell. Biochem. 2008, 1354-1368.
9. Barsky S.H., Siegal G.P., Jannotta F., Liotta L.A. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab. Investig. 1983, 49(2:140-147. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/6348406.
10. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24(18:1967-2000.
11. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59(19:5002-5011.
12. Lang S.H., Stower M., Maitland N.J. In vitro modelling of epithelial and stromal interactions in non-malignant and malignant prostates. Br. J. Cancer 2000, 82:990-997.
13. Dawson L.A., Maitland N.J., Turner A.J., Usmani B.A. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br. J. Cancer 2004, 90(8:1577-1582. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2409712&tool=pmcentrez&rendertype=abstract.
14. Cunha G.R., Hayward S.W., Wang Y.Z., Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 2003, 107(1:1-10.
15. Berry P.A., Maitland N.J., Collins A.T. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol. Cell. Endocrinol. 2008, 288(1-2:30-37.
16. Strand D.W., Goldstein A.S. The many ways to make a luminal cell and a prostate cancer cell. Endocr. Relat. Cancer 2015, 22:187-197.
17. Pierce G.B., Speers W.C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 1988, 1996-2004.
18. Hong D., Gupta R., Ancliff P., Atzberger A., Brown J., Soneji S., et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008, 319(5861:336-339.
19. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194(4260:23-28.
20. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5:759-767.
21. Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 2013, 123(11:4918-4922.
22. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz La, Kinzler K.W. Cancer genome landscapes. Science 2013, 339(6127:1546-1558. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3749880&tool=pmcentrez&rendertype=abstract.
23. Slaughter D.P., Southwick H.W., Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953, 6(5:963-968.
24. Mohan M., Jagganathan N. Oral field cancerization: an update on current concepts. Oncol. Rev. 2014, 8(1:244. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419611/.
25. Nonn L., Ananthanarayanan V., Gann P.H. Evidence for field cancerization of the prostate. Prostate 2009, 15;69(13:1470-1479.
26. Mehrotra J., Varde S., Wang H., Chiu H., Vargo J., Gray K., et al. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008, 68(2:152-160. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/18058812.
27. Cooper C. Analysis of the genetic phylogeny of multifocal prostate cancer. Nat. Genet. 2015, 47(4:367-372.
28. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329(5991:568-571. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2917982&tool=pmcentrez&rendertype=abstract.
29. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457(7229:608-611.
30. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 717-728.
31. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17(3:313-319.
32. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65(23:10946-10951.
33. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469(7330:356-361.
34. Calabrese P., Tavaré S., Shibata D. Pretumor progression: clonal evolution of human stem cell populations. Am. J. Pathol. 2004, 164(4:1337-1346.
35. Tomasetti C., Vogelstein B. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015, 347(6217:78-81. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25554788.
36. Albini A., Cavuto S., Apolone G., Noonan D.M. Strategies to prevent "bad luck" in cancer. J. Natl. Cancer Inst. 2015.
37. IACR Most types of cancer not due to "bad luck". IARC responds to scientific article claiming that environmental and lifestyle factors account for less than one third of cancers. Cent. Eur. J. Public Health 2015, 23(1:87. (Press Release No. 231 13 January 2015.
38. Potter J., Prentice R. Cancer risk: tumours excluded. Science 2015, 347(6223:727. (80-.
39. Song M., Giovannucci E. Cancer risk: many factors contribute. Science 2015, 347(6223:729. (80-.
40. Wild C., Brennan P., Plummer M., Bray F., Straif K., Zavadil J. Cancer risk: role of chance overstated. Science 2015, 347(6223:728. (80-.
41. Gotay C., Dummer T., Spinelli J. Cancer risk: prevention is crucial. Science 2015, 347(6223:728.
42. O'Callaghan M. Cancer risk: accuracy of literature. Science 2015, 347(6223:729. (80-.
43. Maitland N.J., Collins A.T. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection?. J. Cell. Biochem. 2008, 931-939.
44. Johnston M.D., Edwards C.M., Bodmer W.F., Maini P.K., Chapman S.J. Mathematical modeling of cell population dynamics in the colonic crypt and in colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(10:4008-4013.
45. Tomlinson I., Sasieni P., Bodmer W. How many mutations in a cancer?. Am. J. Pathol. 2002.
46. Tomlinson I., Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat. Med. 1999.
47. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 306-313.
48. Ling S., Hu Z., Yang Z., Yang F., Li Y., Lin P., et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. PNAS 2015, (Internet. (1519556112 -. Available from: http://www.pnas.org/content/early/2015/11/11/1519556112.abstract.
49. Williams M.J., Werner B., Barnes C.P., Graham T.A., Sottoriva A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 2016.
50. Hjelmeland A.B., Wu Q., Heddleston J.M., Choudhary G.S., MacSwords J., Lathia J.D., et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 2011, 18(5:829-840.
51. Ricci-Vitiani L., Pallini R., Biffoni M., Todaro M., Invernici G., Cenci T., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468(7325:824-828.
52. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468(7325:829-833.
53. Collins A.T., Habib F.K., Maitland N.J., Neal D.E. Identification and isolation of human prostate epithelial stem cells based on alpha(2beta(1-integrin expression. J. Cell Sci. 2001, 114(Pt 21:3865-3872.
54. Sneddon J.B., Zhen H.H., Montgomery K., van de Rijn M., Tward A.D., West R., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(40:14842-14847.
55. Watt F.M., Hogan B.L. Out of Eden: stem cells and their niches. Science 2000, 287(5457:1427-1430.
56. Jones D.L., Wagers A.J. No place like home: anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 2008, 9(1:11-21.
57. Lang S.H., Anderson E., Fordham R., Collins A.T. Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro. Stem Cells Dev. 2010, 19(4:537-546.
58. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 2011, 121(4:1298-1312.
59. Yatabe Y., Tavaré S., Shibata D. Investigating stem cells in human colon by using methylation patterns. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(19:10839-10844.
60. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011;8(2:97-106.
61. Figueiredo B.C., Sandrini R., Zambetti G.P., Pereira R.M., Cheng C., Liu W., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J. Med. Genet. 2006, 91-96.
62. Baker A.M., Cereser B., Melton S., Fletcher A.G., Rodriguez-Justo M., Tadrous P.J., et al. Quantification of crypt and stem cell evolution in the normal and neoplastic human colon. Cell Rep. 2014, 8(4:940-947. (Internet. The Authors. (Available from: http://dx.doi.org/10.1016/j.celrep.2014.07.019.
63. Huels D.J., Sansom O.J. Stem vs Non-stem Cell Origin of Colorectal Cancer. Br. J. Cancer 2015, 113(1:1-5. (Internet. Cancer Research UK. (Available from: http://dx.doi.org/10.1038/bjc.2015.214/n10.1038/bjc.2015.214.
64. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997.
65. He X., Marchionni L., Hansel D.E., Yu W., Sood A., Yang J., et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 2009.
66. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J. Identification of a cancer stem cell in human brain tumors. Pathobiology 2003.
67. Al-Hajj M., Wicha M., Benito-Hernandez A., Morrison S., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. PNAS 2003, 100(11:3983-3988.
68. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007.
69. Feng D., Peng C., Li C., Zhou Y., Li M., Ling B., et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol. Rep. 2009.
70. Rutella S., Bonanno G., Procoli A., Mariotti A., Corallo M., Prisco M.G., et al. Human cancer biology cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin. Cancer Res. 2009.
71. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2007.
72. Ma S., Chan K.W., Hu L., Lee T.K.W., Wo J.Y.H., Ng I.O.L., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007.
73. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008.
74. Fang D., Nguyen T.K., Leishear K., Finko R., Kulp A.N., Hotz S., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005.
75. Matsui W., Huff C.A., Wang Q., Malehomr M.T., Barber J., Tanhehco Y., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004.
76. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007.
77. Zhang S., Balch C., Chan M.W., H-C Lai, Matei D., Schilder J.M., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008.
78. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989, 2:33-50.
79. Maitland N.J., Frame F.M., Polson E.S., Lewis J.L., Collins A.T. Prostate cancer stem cells: do they have a basal or luminal phenotype?. Horm. Cancer 2011, 2(1:47-61.
80. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. J. Cell Sci. 2004, 117(Pt 16:3539-3545.
81. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol. 2008, 9(5:R83.
82. Polson E.S., Lewis J.L., Celik H., Mann V.M., Stower M.J., Simms M.S., et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat. Commun. 2013, 4:1623. (Internet. Nature Publishing Group. (Available from: http://www.nature.com/ncomms/journal/v4/n3/full/ncomms2627.html#figures.
83. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25(12:1696-1708.
84. Lukacs R.U., Memarzadeh S., Wu H., Witte O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 2010, 7(6:682-693. (Internet. Elsevier Inc. (Available from: http://dx.doi.org/10.1016/j.stem.2010.11.013.
85. Gong C., Liao H., Guo F., Qin L., Qi J. Implication of expression of Nanog in prostate cancer cells and their stem cells. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2012, 32(2:242-246. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/22528228.
86. Karthaus W.R., Iaquinta P.J., Drost J., Gracanin A., Van Boxtel R., Wongvipat J., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014, 159:163-175. (Internet. (Available from: http://dx.doi.org/10.1016/j.cell.2014.08.017.
87. Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD. Heterogeneity of Clonogenic Cells in Acute Myeloblastic Leukemia.
88. Li L., Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010.
89. Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011, 19(1:138-152.
90. Gibbs K.D., Jager A., Crespo O., Goltsev Y., Trejo A., Richard C.E., et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell 2012, 10(2:210-217.
91. Meyer M.J., Fleming J.M., Lin A.F., Hussnain S.A., Ginsburg E., Vonderhaar B.K. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 2010, 70(11:4624-4633.
92. Schober M., Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-β and integrin/focal adhesion kinase (FAK signaling. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(26:10544-10549.
93. Stewart J.M., Shaw P.A., Gedye C., Bernardini M.Q., Neel B.G., Ailles L.E. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(16:6468-6473.
94. Liu H., Patel M.R., Prescher J.A., Patsialou A., Qian D., Lin J., et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(42:18115-18120.
95. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3:313-323.
96. Ghajar C.M. Metastasis prevention by targeting the dormant niche. Nat. Rev. Cancer 2015, 15(4:238-247. (Internet. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. (Available from: http://dx.doi.org/10.1038/nrc3910.
97. Frame F.M., Pellacani D., Collins A.T., Simms M.S., Mann V.M., Jones G., et al. HDAC Inhibitor Confers Radiosensitivity to Prostate Stem-like Cells 2013, Vol. 109.
98. Gleason D.F. Classification of prostatic carcinomas. Cancer Chemother. Rep. 1966, 50(3:125-128.
99. Lavery H.J., Droller M.J. Do gleason patterns 3 and 4 prostate cancer represent separate disease states?. J. Urol. 2012, 188(5:1667-1675. (Internet. Elsevier Inc. (Available from: http://dx.doi.org/10.1016/j.juro.2012.07.055.
100. Cohen M.S., Hanley R.S., Kurteva T., Ruthazer R., Silverman M.L., Sorcini A., et al. Comparing the gleason prostate biopsy and gleason prostatectomy grading system: The Lahey Clinic Medical Center experience and an international meta-analysis. Eur. Urol. 2008, 54(2:371-381.
101. Penney K.L., Stampfer M.J., Jahn J.L., Sinnott J.A., Flavin R., Rider J.R., et al. Gleason grade progression is uncommon. Cancer Res. 2013, 73(16:5163-5168.
102. Kovtun I.V., Cheville J.C., Murphy S.J., Johnson S.H., Zarei S., Kosari F., et al. Lineage relationship of gleason patterns in gleason score 7 prostate cancer. Cancer Res. 2013, 73:3275-3284.
103. Eggener S.E., Scardino P.T., Walsh P.C., Han M., Partin A.W., Trock B.J., et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 2011, 185(3:869-875. (Internet. American Urological Association Education and Research, Inc. (Available from: http://dx.doi.org/10.1016/j.juro.2010.10.057.
104. Hernandez D.J., Nielsen M.E., Han M., Trock B.J., Partin A.W., Walsh P.C., et al. Natural history of pathologically organ-confined (pT2, Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008, 72(1:172-176. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2603620&tool=pmcentrez&rendertype=abstract.
105. Trock B.J., Guo C.C., Gonzalgo M.L., Magheli A., Loeb S., Epstein J.I. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J. Urol. 2009, 182(4:1364-1370. (Internet. Elsevier Inc. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/19683280.
106. True L., Coleman I., Hawley S., Huang C.-Y., Gifford D., Coleman R., et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(29:10991-10996. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1544162&tool=pmcentrez&rendertype=abstract.
107. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 2007, 39(1:41-51.
108. Kulac I., Haffner M.C., Yegnasubramanian S., Epstein J.I., De Marzo A.M. Should Gleason 6 be labeled as cancer?. Curr. Opin. Urol. 2015, 25(3:125-238.
109. Epstein J.I., Egevad L., Amin M.B., Delahunt B., Srigley J.R., PA Humphrey, et al. The 2014 International Society of Urological Pathology (ISUP consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 2015, (E-pub..
110. Essers M.A.G., Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol. Oncol. 2010.
111. Foudi A., Hochedlinger K., Van Buren D., Schindler J.W., Jaenisch R., Carey V., et al. Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. Nat. Biotechnol. 2009, 27(1:84-90.
112. Cheshier S.H., Prohaska S.S., Weissman I.L. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. 2007, 16(5:707-717. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17999593.
113. Trumpp A., Essers M., Wilson A. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 2010.
114. Wilson A., Laurenti E., Oser G., van der Wath R.C., Blanco-Bose W., Jaworski M., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008, 135(6:1118-1129.
115. Chakkalakal J.V., Jones K.M., Basson M.A., Brack A.S. The aged niche disrupts muscle stem cell quiescence. Nature 2012.
116. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy.
117. Cairns J. Mutation selection and the natural history of cancer. Nature 1975, 255(5505:197-200. (Internet. (Available from: http://www.nature.com/nature/journal/v255/n5505/abs/255197a0.html.
118. Cairns J. Perspectives Anecdotal, Historical and Critical Commentaries on Genetics Cancer and the Immortal Strand Hypothesis.
119. Rando T.A. The immortal strand hypothesis: segregation and reconstruction. Cell 2007, 129(7:1239-1243. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17604710.
120. Roth R.B., Samson L.D. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 2002, 62(3:656-660. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/11830515.
121. Lark K.G., Consigli R.A., Minocha H.C. Segregation of sister chromatids in mammalian cells. Science 1966, 154(753:1202-1205.
122. Potten C.S., Owen G., Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J. Cell Sci. 2002, 115(Pt 11:2381-2388.
123. Conboy M.J., Karasov A.O., Rando T.A. High incidence of non-random template strand segregation and asymmetric fate determination in dividing stem cells and their progeny. PLoS Biol. 2007, 5(7.
124. Kiel M.J., He S., Ashkenazi R., Gentry S.N., Teta M., Kushner J.A., et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 2007, 449(7159:238-242.
125. Steinhauser M.L., Bailey A.P., Senyo S.E., Guillermier C., Perlstein T.S., Gould A.P., et al. Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature 2012, 481(7382:516-519. (Internet. Nature Publishing Group. Available from: http://dx.doi.org/10.1038/nature10734.
126. Tomasetti C., Bozic I. The (not so immortal strand hypothesis. Stem Cell Res. 2015, 14(2:238-241. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25700960.
127. Merok J.R., Lansita J.A., Tunstead J.R., Sherley J.L. Cosegregation of chromosomes containing immortal DNA strands in cells that cycle with asymmetric stem cell kinetics. Cancer Res. 2002, 62(23:6791-6795. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/12460886.
128. Shibata M., Shen M.M. Stem cells in genetically-engineered mouse models of prostate cancer. Endocr. Relat. Cancer. 2015, 22(6:T199-208.
129. Tuxhorn J.A., McAlhany S.J., Dang T.D., Ayala G.E., Rowley D.R. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS xenograft model. Cancer Res. 2002, 62(11:3298-3307. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/12036948.
130. Gleave M.E., Hsieh J.T., von Eschenbach A.C., Chung L.W. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol. 1992, 147(4:1151-1159.
131. Leong K.G., Wang B.-E., Johnson L., Gao W.-Q. Generation of a prostate from a single adult stem cell. Nature 2008, 456(7223:804-808.
132. Jiao J., Hindoyan A., Wang S., Tran L.M., Goldstein A.S., Lawson D., et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One 2012.
133. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461(7263:495-500.
134. Chua C.W., Shibata M., Lei M., Toivanen R., Barlow L.J., Bergren S.K., et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat. Cell Biol. 2014, 16:951-961.
135. Wang Z.A., Toivanen R., Bergren S.K., Chambon P., Shen M.M. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep. 2014.
136. Ousset M., Van Keymeulen A., Bouvencourt G., Sharma N., Achouri Y., Simons B.D., et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat. Cell Biol. 2012, 14.
137. Choi N., Zhang B., Zhang L., Ittmann M., Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012, 21:253-265.
138. Wang J., Zhu H.H., Chu M., Liu Y., Zhang C., Liu G., et al. Symmetrical and asymmetrical division analysis provides evidence for a hierarchy of prostate epithelial cell lineages. Nat. Commun. 2014, 5.
139. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67(14:6796-6805.
140. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B., Farrar W.L. CD44+ CD24(- prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008.
141. Qin J., Liu X., Laffin B., Chen X., Choy G., Jeter C.R., et al. The PSA(-/lo prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012, 10(5:556-569. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3348510&tool=pmcentrez&rendertype=abstract.
142. Germann M., Wetterwald A., Guzmán-Ramirez N., Van Der Pluijm G., Culig Z., Cecchini M.G., et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012, 30(6:1076-1086.
143. Maini A., Archer C., Wang C., Haas G. Comparative pathology of benign prostatic hyperplasia and prostate cancer. In Vivo (Brooklyn 1997, 11(4:293-299. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/9292295.
144. Sharma P., Schreiber-Agus N. Mouse models of prostate cancer. Oncogene 1999, 18(38:5349-5355.
145. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4:683-692. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17320506.
146. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4:693-705. (Internet. (Available from: http://www.sciencedirect.com/science/article/pii/S0092867407001845.
147. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007, 447(7143:425-432.
148. Tollervey J.R., Lunyak V.V. Judge, jury and executioner of stem cell fate. Epigenetics 2012, 7(8:823-840.
149. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer program in Computational Biology 2 Program in Human Oncology and Pathogenesis (HOPP. Cancer Cell 2010, 18:11-22.
150. Grasso C.S., Wu Y.-M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 239-243.
151. Tan J., Yang X., Jiang X., Zhou J., Li Z., Lee P.L., et al. Integrative epigenome analysis identifies a polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis. 2014, 5:e1324. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4123077&tool=pmcentrez&rendertype=abstract.
152. Hahn M.A., Li A.X., Wu X., Yang R., Drew D.A., Rosenberg D.W., et al. Activation of cancer-promoting genes in colorectal tumors loss of the polycomb mark from bivalent promoters leads to loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res. 2014, 74:3617-3629. (Internet. (Available from: http://cancerres.aacrjournals.org/content/suppl/2014/05/01/0008-5472.CAN-13-3147.DC1.html.
153. Chapman-Rothe N., Curry E., Zeller C., Liber D., Stronach E., Gabra H., et al. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene 2013, 32(38:4586-4592. (Internet. Nature Publishing Group. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/23128397.
154. Pellacani D., Kestoras D., Droop A.P., Frame F.M., Berry P.A., Lawrence M.G., et al. DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell Death Differ. 2014, 21(5:761-773. (Internet. Nature Publishing Group. (Available from: http://www.ncrbi.nlm.nih.gov/pubmed/24464224.
155. Wang Q., Williamson M., Bott S., Brookman-Amissah N., Freeman A., Nariculam J., et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007, 26(45:6560-6565.
156. Navarro J.-M., Touzart A., Pradel L.C., Loosveld M., Koubi M., Fenouil R., et al. Site- and allele-specific polycomb dysregulation in T-cell leukaemia. Nat. Commun. 2015, 6:6094. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25615415.
157. Yamamoto H., Oue N., Sato A., Hasegawa Y., Matsubara A., Yasui W., et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010, 29(14:2036-2046. (Internet. Nature Publishing Group. (Available from: http://dx.doi.org/10.1038/onc.2009.496.
158. Miyamoto D.T., Zheng Y., Wittner B.S., Lee R.J., Zhu H., Broderick K.T., et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 2015, 349(6254:1351-1356. ((80 18.
159. Bapat S.A., Jin V., Berry N., Balch C., Sharma N., Kurrey N., et al. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics 2010, 5(8:716-729.
160. Kreso A., O'Brien C.A., van Galen P., Gan O.I., Notta F., Brown A.M., et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013, 339(6119:543-548. (80- Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/23239622.
161. Marinov G.K., Williams B.A., McCue K., Schroth G.P., Gertz J., Myers R.M., et al. From single-cell to cell-pool transcriptomes: stochasticity in gene expression and RNA splicing. Genome Res. 2014, 24(3:496-510.
162. Lee M.-C.W., Lopez-Diaz F.J., Khan S.Y., Tariq M.A., Dayn Y., Vaske C.J., et al. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc. Natl. Acad. Sci. U. S. A. 2014, (Internet, (E4726-35 p. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4226127&tool=pmcentrez&rendertype=abstract.
163. Ting D.T., Wittner B.S., Maheswaran S.-M., Haber Correspondence D.A. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. CELREP 2014, 8:1905-1918.
164. Patel A.P., Tirosh I., Trombetta J.J., Shalek A.K., Gillespie S.M., Wakimoto H., et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014.
165. Van Loo P., Voet T. Single cell analysis of cancer genomes. Curr. Opin. Genet. Dev. 2014, 24:82-91. (Internet. (Available from: http://dx.doi.org/10.1016/j.gde.2013.12.004.
166. Gendrel A.-V., Attia M., Chen C.-J., Diabangouaya P., Servant N., Barillot E., et al. Developmental dynamics and disease potential of random monoallelic gene expression. Dev. Cell 2014, 28(4:366-380. (Internet. Elsevier. (Available from: http://www.cell.com/article/S1534580714000574/fulltext.
167. Lanie M., Eckersley-Maslin A., Thybert D., Bergmann J.H., Marioni J.C., Flicek P., et al. Random monoallelic gene expression increases upon embryonic stem cell differentiation. Dev. Cell 2014, 28:351-365. (Internet. (Available from: http://dx.doi.org/10.1016/j.devcel.2014.01.017.
168. Lo H.S.S., Wang Z., Hu Y., Yang H.H.H., Gere S., Buetow K.H.H., et al. Allelic variation in gene expression is common in the human genome. Genome Res. 2003, 13(8:1855. (Internet. (Available from: http://genome.cshlp.org/content/13/8/1855.short.
169. Gimelbrant A., Hutchinson J.N., Thompson B.R., Chess A. Widespread monoallelic expression on human autosomes. Science 2007, 318(5853:1136-1140. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/18006746.
170. Nag A., Savova V., Fung H.L., Miron A., Yuan G.C., Zhang K., et al. Chromatin signature of widespread monoallelic expression. Elife 2013, 2013(2:1-19.
171. Metsalu T., Viltrop T., Tiirats A., Rajashekar B., Reimann E., Kõks S., et al. Using RNA sequencing for identifying gene imprinting and random monoallelic expression in human placenta. Epigenetics 2014, 9(10:1397-1409. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25437054.
172. Borel C., Ferreira P.G., Santoni F., Delaneau O., Fort A., Popadin K.Y., et al. Biased allelic expression in human primary fibroblast single cells. Am. J. Hum. Genet. 2015, 96(1:70-80. (Internet. (Available from: http://www.sciencedirect.com/science/article/pii/S0002929714005035.
173. Wang J., Valo Z., Bowers C.W., Smith D.D., Liu Z., Singer-Sam J. Dual DNA methylation patterns in the CNS reveal developmentally poised chromatin and monoallelic expression of critical genes. PLoS One 2010, 5(11:e13843. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2973945&tool=pmcentrez&rendertype=abstract.
174. Gutierrez-Arcelus M., Lappalainen T., Montgomery S.B., Buil A., Ongen H., Yurovsky A., et al. Passive and active DNA methylation and the interplay with genetic variation in gene regulation. Elife 2013, 2013(2:1-18.
175. Nag A., Vigneau S., Savova V., Zwemer L.M., Gimelbrant A.A., Yurovsky A., et al. Chromatin signature identifies monoallelic gene expression across mammalian cell types. G3 Genes|Genomes|Genetics. 2015, 5(8:1713-1720.
176. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006, 21;125(2:315-326.
177. Vincent A., Kazmierczak C., Duchêne B., Jonckheere N., Leteurtre E., Van Seuningen I., et al. Cryosectioning the intestinal crypt-villus axis: an ex vivo method to study the dynamics of epigenetic modifications from stem cells to differentiated cells. Stem Cell Res. 2015, 14:105-113. (Internet. (Available from: http://dx.doi.org/10.1016/j.scr.2014.12.002.
178. Ohm J.E., Mcgarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and silencing in adult cancers. Nat. Genet. 2007, 39(2:237-242.
179. Tan J., Yang X., Jiang X., Zhou J., Li Z., Lee P., et al. Integrative epigenome analysis identifies a polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis. 2014, 5.
180. Rodriguez J., Muñ Oz M., Vives L., Frangou C.G., Groudine M., Peinado M.A., et al. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. PNAS 2008, 16;105(50:19809-19814.
181. Iliou M.S., Lujambio A., Portela A., Brüstle O., Koch P., Andersson-Vincent H., et al. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Outi Hovatta Manel Esteller Epigenetics 2011, 611:1344-1353. (Internet. (Available from: http://www.tandfonline.com/loi/kepi20.
182. Lin B., Lee H., Yoon J.-G., Madan A., Wayner E., Tonning S., et al. Global analysis of H3K4me3 and H3K27me3 profiles in glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor suppressor gene. Oncotarget 2015, 6(7. (Internet. (Available from: www.impactjournals.com/oncotarget.
183. Raval A., Tanner S.M., Byrd J.C., Angerman E.B., Perko J.D., Chen S.-S., et al. Downregulation of death-associated protein kinase 1 (DAPK1 in chronic lymphocytic leukemia. Cell 2007.
184. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153(3:666-677.
185. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Grönberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007.
186. Maitland N.J., Collins A.T. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection?. J. Cell. Biochem. 2008, 105:931-939.
187. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995, 45(3:542-549.
188. Adler H.L., McCurdy M.A., Kattan M.W., Timme T.L., Scardino P.T., Thompson T.C. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J. Urol. 1999, 161(1:182-187.
189. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 2000, 6(7:2702-2706.
190. Kroon P., Berry P.A., Stower M.J., Rodrigues G., Mann V.M., Simms M., et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013, 73(16:5288-5298.
191. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 693-706. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/19878981.
192. Schroeder A., Herrmann A., Cherryholmes G., Kowolik C., Buettner R., Pal S., et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014, 74(4:1227-1237.
193. Guryanova O.A., Wu Q., Cheng L., Lathia J.D., Huang Z., Yang J., et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011, 19(4:498-511.
194. Han Z., Wang X., Ma L., Chen L., Xiao M., Huang L., et al. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget 2014, 5(18:8416-8428. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4226693&tool=pmcentrez&rendertype=abstract.
195. Don-Doncow N., Escobar Z., Johansson M., Kjellström S., Garcia V., Munoz E., et al. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J. Biol. Chem. 2014, 289(23:15969-15978. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4047371&tool=pmcentrez&rendertype=abstract.
196. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478(7369:399-403. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/22012397.
197. Jin R., Sterling J.A., Edwards J.R., DeGraff D.J., Lee C., Park S.I., et al. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PLoS One 2013, 8(4:e60983. (Internet. (Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060983#pone-0060983-g007/nhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3618119&tool=pmcentrez&rendertype=abstract.
198. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12(8:715-723. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/21772280.
199. Hägglöf C., Bergh A. The stroma-a key regulator in prostate function and malignancy. Cancers (Basel 2012, 4(2:531-548.
200. Hall J.A., Maitland N.J., Stower M., Lang S.H. Primary prostate stromal cells modulate the morphology and migration of primary prostate epithelial cells in type 1 collagen gels. Cancer Res. 2002, 62(1:58-62. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/11782359.
201. Franco O.E., Shaw A.K., Strand D.W., Hayward S.W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21(1:33-39. (Internet. Elsevier Ltd. (Available from: http://dx.doi.org/10.1016/j.semcdb.2009.10.010.
202. Ao M., Franco O.E., Park D., Raman D., Williams K., Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007, 67(9:4244-4253.
203. Vindrieux D., Escobar P., Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr. Relat. Cancer 2009, 16:663-673.
204. Strasner A., Karin M. Immune infiltration and prostate cancer. Front Oncol. 2015, 5:128. (Internet, Frontiers. (Available from: http://journal.frontiersin.org/article/10.3389/fonc.2015.00128/abstract.
205. Sfanos K.S., Bruno T.C., Meeker A.K., De Marzo A.M., Isaacs W.B., Drake C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009, 69(15:1694-1703.
206. Ebelt K., Babaryka G., Frankenberger B., Stief C.G., Eisenmenger W., Kirchner T., et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer 2009, 45(9:1664-1672. (Internet. Elsevier Ltd. (Available from: http://dx.doi.org/10.1016/j.ejca.2009.02.015.
207. Nonomura N., Takayama H., Nakayama M., Nakai Y., Kawashima A., Mukai M., et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011, 107(12:1918-1922. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/21044246.
208. Gannon P.O., Poisson A.O., Delvoye N., Lapointe R., Mes-Masson A.M., Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 2009, 348(1-2:9-17. (Internet. Elsevier B.V. (Available from: http://dx.doi.org/10.1016/j.jim.2009.06.004.
209. Woo J.R., Liss M.A., Muldong M.T., Palazzi K., Strasner A., Ammirante M., et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J. Transl. Med. 2014, 12(1:30. (J Transl Med, Internet, (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3914187&tool=pmcentrez&rendertype=abstract.
210. Ammirante M., Kuraishy A.I., Shalapour S., Strasner A., Ramirez-Sanchez C., Zhang W., et al. An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev. 2013, 27(13:1435-1440. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3713424&tool=pmcentrez&rendertype=abstract.
211. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001, 411(6835:390-395.
212. Nelson W.G., Demarzo A.M., Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treat. Res. 2014, 159:51-68. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/24114474.
213. Norrish A.E., Ferguson L.R., Knize M.G., Felton J.S., Sharpe S.J., Jackson R.T. Heterocyclic amine content of cooked meat and risk of prostate cancer. J. Natl. Cancer Inst. 1999, 91(23:2038-2044.
214. Michaud D.S., Augustsson K., Rimm E.B., Stampfer M.J., Willet W.C., Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. Cancer Causes Control 2001, 12(6:557-567. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/11519764.
215. Tang D., Liu J.J., Rundle A., Neslund-Dudas C., Savera A.T., Bock C.H., et al. Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol. Biomark. Prev. 2007, 16(April:803-808.
216. Sugimura T., Wakabayashi K., Nakagama H., Nagao M. Heterocyclic amines: mutagens/carcinogens produced during cooking of meet and fish. Cancer Sci. 2004, 95(4:290-299.
217. Inaguma S., Takahashi S., Ohnishi H., Suzuki S., Cho Y.-M., Shirai T. High susceptibility of the ACI and spontaneously hypertensive rat (SHR strains to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP prostate carcinogenesis. Cancer Sci. 2003, 94(11:974-979. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/14611674.
218. Nakai Y., Nelson W.G., De Marzo A.M. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007, 67(3:1378-1384. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17264317.
219. Sfanos K., Canene-Adams K., Hempel H., Yu S., Simons B., Schaeffer A., et al. Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP-induced cancer at multiple sites. Cancer Prev. Res. 2015, 8(8:683-692. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25990088.
220. Patel S.A.A., Gooderham N.J. Interleukin-6 promotes dietary carcinogen-induced DNA damage in colorectal cancer cells. R. Soc. Chem. 2015, 4(4:858-866. (Toxicol Res, Internet, (Available from: http://pubs.rsc.org/en/content/articlehtml/2015/tx/c5tx00068h.
221. Weinberger M., Cytron S., Servadio C., Block C., Rosenfeld J.B., Pitlik S.D. Prostatic abscess in the antibiotic era. Rev. Infect. Dis. 1988, 10(2:239-249.
222. Krieger J.N., Riley D.E., Roberts M.C., Berger R.E. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J. Clin. Microbiol. 1996, 34(12:3120-3128. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=229469&tool=pmcentrez&rendertype=abstract.
223. Anderson M., Handley J., Hopwood L., Murant S., Stower M., Maitland N.J. Analysis of prostate tissue DNA for the presence of human papillomavirus by polymerase chain reaction, cloning, and automated sequencing. J. Med. Virol. 1997, 52:8-13.
224. Hrbacek J., Urban M., Hamsikova E., Tachezy R., Eis V., Brabec M., et al. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study. BMC Cancer 2011, 11(1:53. (Internet. BioMed Central Ltd. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3039631&tool=pmcentrez&rendertype=abstract.
225. Caini S., Gandini S., Dudas M., Bremer V., Severi E., Gherasim A. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 2014, 38(4:329-338. (Internet. Elsevier Ltd. (Available from: http://dx.doi.org/10.1016/j.canep.2014.06.002.
226. Perry A., Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev. Anti-Infect. Ther. 2011, 9(12:1149-1156. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/22114965.
227. Cohen R.J., Shannon B.A., McNeal J.E., Shannon T., Garrett K.L. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution?. J. Urol. 2005, 173(6:1969-1974. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/15879794.
228. Song C., Chen H., Wang T., Zhang W., Ru G., Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate 2015, 1;75(5:500-516.
229. Fassi Fehri L., Mak T.N., Laube B., Brinkmann V., Ogilvie L.A., Mollenkopf H., et al. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int. J. Med. Microbiol. 2011, 301(1:69-78. (Internet. Elsevier GmbH. (Available from: http://dx.doi.org/10.1016/j.ijmm.2010.08.014.
230. Shinohara D.B., Vaghasia A.M., Yu S.H., Mak T.N., Brüggemann H., Nelson W.G., et al. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate 2013, 73(9:1007-1015.
231. Pascale M., Pracella D., Barbazza R., Marongiu B., Roggero E., Bonin S., et al. Is human papillomavirus associated with prostate cancer survival?. Dis. Markers 2013, 35(6:607-613. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3830784&tool=pmcentrez&rendertype=abstract.
232. Singh N., Hussain S., Kakkar N., Singh S.K., Sobti R.C., Bharadwaj M. Implication of high risk Human papillomavirus HR-HPV infection in prostate cancer in Indian population - A pioneering case-control analysis. Sci. Rep. 2015, 5:7822. (Internet. (Available from: http://www.nature.com/doifinder/10.1038/srep07822.
233. Bergh J., Marklund I., Gustavsson C., Wiklund F., Grönberg H., Allard A., et al. No link between viral findings in the prostate and subsequent cancer development. Cancer Res. UK 2007, 96(1:137-139. (Br J Cancer, Internet, (Available from: http://dx.doi.org/10.1038/sj.bjc.6603480.
234. Strickler H.D., Schiffman M.H., Shah K.V., Rabkin C.S., Schiller J.T., Wacholder S., et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer Prev. 1998, 7(4:305-313. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/9806119.
235. Thompson M.P., Kurzrock R. Epstein-Barr virus and cancer. Clin. Cancer Res. 2004, 10:803-821.
236. Whitaker N.J., Glenn W.K., Sahrudin A., Orde M.M., Delprado W., Lawson J.S. Human papillomavirus and Epstein Barr virus in prostate cancer: koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer. Prostate 2013, 73(3:236-241.
237. Zambrano A., Kalantari M., Simoneau A., Jensen J.L., Villarreal L.P. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 2002, 53(4:263-276. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/12430138.
238. Das D., Wojno K., Imperiale M.J. BK virus as a cofactor in the etiology of prostate cancer in its early stages. J. Virol. 2008, 82(6:2705-2714.
239. Keller X.E., Kardas P., Acevedo C., Sais G., Poyet C., Banzola I., et al. Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer. Oncotarget 2015, 6(8. (Internet. (Available from: www.impactjournals.com/oncotarget.
240. Chen Y., Wei J. Identification of pathogen signatures in prostate cancer using RNA-seq. PLoS One 2015, 10(6:e0128955. (Internet. (Available from: http://dx.doi.org/10.1371/journal.pone.0128955/nhttp://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0128955&representation=PDF.
241. Riley D.E., Berger R.E., Miner D.C., Krieger J.N. Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis. J. Clin. Microbiol. 1998, 36(6:1646-1652.
242. Krieger J.N., Riley D.E., Vesella R.L., Miner D.C., Ross S.O., Lange P.H. Bacterial DNA sequences in prostate tissue from patients with prostate cancer and chronic prostatitis. J. Urol. 2000, 164(4:1221-1228. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/10992370.
243. Sfanos K.S., Sauvageot J., Fedor H.L., Dick J.D., De Marzo A.M., Isaacs W.B. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 2008, 68(3:306-320. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/18163428.
244. Birkeland S.A., Storm H.H., Lamm L.U., Barlow L., Blohmé I., Forsberg B., et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int. J. Cancer 1995, 60(2:183-189. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/7829213.
245. Mahmud S., Franco E., Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br. J. Cancer 2004, 90(1:93-99. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2395299&tool=pmcentrez&rendertype=abstract.
246. Platz E.A. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomark. Prev. 2005, 14(2:390-396. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/15734963.
247. Jafari S., Etminan M., Afshar K. Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can. Urol. Assoc. J. 2009, 3(4:323-330. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2723875&tool=pmcentrez&rendertype=abstract.
248. Gurel B., Lucia M.S., Thompson I.M., Goodman P.J., Tangen C.M., Kristal A.R. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomark. Prev. 2014, 23(5:847-856.
249. Sfanos K.S., De Marzo A.M. Prostate cancer and inflammation: the evidence. Histopathology 2012, 60(1:199-215. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4029103&tool=pmcentrez&rendertype=abstract.
250. Putzi M.J., De Marzo A.M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000, 56(5:828-832.
251. De Marzo A.M., Marchi V.L., Epstein J.I., Nelson W.G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 1999, 155(6:1985-1992. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1866955&tool=pmcentrez&rendertype=abstract.
252. Bethel C.R., Faith D., Li X., Guan B., Hicks J.L., Lan F., et al. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with Gleason score and chromosome 8p deletion. Cancer Res. 2006, 66(21:10683-10690.
253. Ruska K.M., Sauvageot J., Epstein J.I. Histology and cellular kinetics of prostatic atrophy. Am. J. Surg. Pathol. 1998, 22(9:1073-1077.
254. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7(1:21-33.
255. Ushijima T. Epigenetic field for cancerization. J. Biochem. Mol. Biol. 2007, 40(2:142-150.
256. Vral A., Magri V., Montanari E., Gazzano G., Gourvas V., Marras E., et al. Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int. J. Oncol. 2012, 41(6:1950-1958. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3583840&tool=pmcentrez&rendertype=abstract.
257. Eminaga O., Hinkelammert R., Abbas M., Titze U., Eltze E., Bettendorf O., et al. High-grade prostatic intraepithelial neoplasia (HGPIN and topographical distribution in 1374 prostatectomy specimens: existence of HGPIN near prostate cancer. Prostate 2013, 73(February:1115-1122.
258. Bostwick D.G., Qian J. High-grade prostatic intraepithelial neoplasia. Mod. Pathol. 2004, 17(3:360-379.
259. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 1993, 150(2 Pt 1:379-385. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/8326560.
260. Bostwick D.G. The pathology of early prostate cancer. CA - Cancer J. Clin. 1989, 39(6:376-393. (Internet. (Available from: http://onlinelibrary.wiley.com/doi/10.3322/canjclin.39.6.376/abstract.
261. Haffner M.C., Weier C., Xu M.M., Vaghasia A., Gürel B., Gümükaya B., et al. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN and intraductal carcinoma through retrograde glandular colonization. J. Pathol. 2015.
262. Perner S., Mosquera J.-M., Demichelis F., Hofer M.D., Paris P.L., Simko J., et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31(6:882-888.
263. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
264. Herawi M., Kahane H., Cavallo C., Epstein J.I. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J. Urol. 2006, 175(1:121-124.
265. Rich A.R. On the frequency of occurrence of occult carcinoma of the prostate. J. Urol. 1935, 33(3.
266. Franks L.M. Latent carcinoma of the prostate. J. Pathol. Bacteriol. 1954, 68(2:603-616.
267. Haas G.P., Delongchamps N., Brawley O.W., Wang C.Y., de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can. J. Urol. 2008.
268. Lilja H., Ulmert D., Björk T., Becker C., Serio A.M., Nilsson J.-A., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol. 2007, 25(4:431-436. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17264339.
269. Loeb S., Carter H.B., Catalona W.J., Moul J.W., Schroder F.H. Baseline prostate-specific antigen testing at a young age. Eur. Urol. 2012, 61:1-7.
270. Martin R.M. Commentary: prostate cancer is omnipresent, but should we screen for it?. Int. J. Epidemiol. 2007.
271. Briganti A., Capitanio U., Suardi N., Gallina A., Salonia A., Bianchi M., et al. Benign prostatic hyperplasia and its aetiologies. Eur. Urol. Suppl. 2009, 8:865-871.
272. Dermer G.B. Basal cell proliferation in benign prostatic hyperplasia. Cancer 1978, 41(5:1857-1862.
273. Rane J.K., Greener S., Frame F., Mann V.M., Simms M.S., Collins A.T., et al. Telomerase activity and telomere length in human benign prostatic hyperplasia stem-like cells and their progeny implies the existence of distinct basal and luminal cell lineages. Eur. Urol. 2015.
274. O'Sullivan R.J., Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat. Rev. Mol. Cell Biol. 2010, 11(3:171-181. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2842081&tool=pmcentrez&rendertype=abstract.
275. Ding Z., Wu C.J., Jaskelioff M., Ivanova E., Kost-Alimova M., Protopopov A., et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012.
276. Sommerfeld H., Meeker A., Piatyszek M., Bova G., Shay J., Coffey D.S. Telomerase activity - a prevalent marker of malignant prostate cancer. Cancer Res. 1996, 56:218-222.
277. Zhang W., Kapusta L.R., Slingerland J.M., Klotz L.H. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res. 1998.
278. Donaldson L., Fordyce C., Gilliland F., Smith A., Feddersen R., Joste N., et al. Association between outcome and telomere DNA content in prostate cancer. J. Urol. 1999, 162(5:1788-1792. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10524936.
279. Meeker A.K., Hicks J.L., Platz E.A., March G.E., Bennett C.J., Delannoy M.J., et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res. 2002.
280. Wymenga L.F., Wisman G.B., Veenstra R., Ruiters M.H., Mensink H.J. Telomerase activity in needle biopsies from prostate cancer and benign prostates. Eur. J. Clin. Investig. 2000.
281. Urquidi V., Tarin D., Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu. Rev. Med. 2000, 51(2:65-79. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/14506175.
282. Heaphy C.M., Yoon G.S., Peskoe S.B., Joshu C.E., Lee T.K., Giovannucci E., et al. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013, 3(10:1130-1141. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3797255&tool=pmcentrez&rendertype=abstract.
283. Rane JK, Simms MS, Maitland NJ. Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al. Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome. Eur. Urol. 2014;65(6:e85-6.
284. Abate-Shen C. Molecular genetics of prostate cancer. Genes Dev. 2000, 14(19:2410-2434. (Internet. (Available from: http://www.genesdev.org/cgi/doi/10.1101/gad.819500.
285. Cesare A.J., Reddel R.R. Alternative lengthening of telomeres: models, mechanisms and implications. Nat. Rev. Genet. 2010, 11(5:319-330. (Internet. Nature Publishing Group. (Available from: http://dx.doi.org/10.1038/nrg2763.
286. Stratton M.R., Stratton M.R., Campbell P.J., Campbell P.J., Futreal P.A., Futreal P.A. The cancer genome. Nature 2009.
287. Tomasetti C., Marchionni L., Nowak M.A., Parmigiani G., Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. PNAS 2015, 6;112(1:118-123.
288. Rosa Mendoza E.S., Moreno E., Caguioa P.B. Predictors of early distant metastasis in women with breast cancer. J. Cancer Res. Clin. Oncol. 2013, 139(4:645-652. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/23283528.
289. Valastyan S., Weinberg R. Tumor metastasis: molecular insights and evolving paradigms. Cell 2012, 147(2:275-292.
290. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9(9:e1001162. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/21980263.
291. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 1989, 63(10:4417-4421. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2476573.
292. Lee S.J., Cho Y.S., Cho M.C., Shim J.H., Lee K.A., Ko K.K., et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J. Immunol. 2001, 167(21:497-504.
293. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007, 121(1:1-14. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2265921&tool=pmcentrez&rendertype=abstract.
294. Dan Robinson A., Van Allen E.M., Sawyers C.L., Chinnaiyan A.M., Robinson D., Wu Y.-M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015, 161(3:1215-1228. (Internet. (Available from: http://dx.doi.org/10.1016/j.cell.2015.05.001.
295. Hall M.C., Navone N.M., Troncoso P., Pollack A., Zagars G.K., von Eschenbach A.C., et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995, 45(3:470-475. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/7879337.
296. Osman I., Drobnjak M., Fazzari M., Ferrara J., Scher H.I., Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res. 1999, 5(August:2082-2088.
297. Heydt C., Kumm N., Fassunke J., Künstlinger H., Ihle M.A., Scheel A., et al. Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. BMC Cancer 2011, 15.
298. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer 1954, 8(1:1-12.
299. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1977, 63(1:125-130. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=267431.
300. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Ashutosh Tewari [Internet]. 1121314(15. Available from: http://www.nature.com/authors/editorial_policies/license.html#terms.
301. Grasso C.S., Wu Y.-M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012.
302. Yu J., Yu J., Mani R.-S., Cao Q., Brenner C.J., Cao X., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17(5:443-454. (Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20478527.
303. Kunderfranco P., Mello-Grand M., Cangemi R., Pellini S., Mensah A., Albertini V., et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 2010, 5(5:e10547. (Internet. (Available from: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010547.
304. Xiang Y., Zhu Z., Han G., Lin H., Xu L., Chen C.D. JMJD3 is a histone H3K27 demethylase. Cell Res. 2007, 17(10:850-857. (Internet. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Available from: http://dx.doi.org/10.1038/cr.2007.83.
305. Xiang Y., Zhu Z., Han G., Ye X., Xu B., Peng Z., et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(49:19226-19231. (Internet. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2148272&tool=pmcentrez&rendertype=abstract.
306. Cloos PaC, Christensen J., Agger K., Maiolica A., Rappsilber J., Antal T., et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442(7100:307-311.
307. Patra S.K., Patra A., Zhao H., Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol. Carcinog. 2002, 33(3:163-171. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/11870882.
308. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Publ. Group 2012, 13(5:297-311. Nat Rev Mol Cell Biol (Internet, (Available from: http://dx.doi.org/10.1038/nrm3327.
309. Ke X.-S., Qu Y., Rostad K., Li W.-C., Lin B., Halvorsen O.J., et al. Genome-wide profiling of Histone H3 Lysine 4 and Lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 2009, 4(3.
310. Ke X.-S., Qu Y., Cheng Y., Li W.-C., Rotter V., Øyan A.M., et al. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics 2010, 11:669.
311. Tomlins S.a, Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.-W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748:644-648. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/16254181.
312. Burkhardt L., Fuchs S., Krohn A., Masser S., Mader M., Kluth M., et al. CHD1 Is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res. 2013.
313. Metzger E., Willmann D., McMillan J., Forne I., Metzger P., Gerhardt S., et al. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat. Chem. Biol. 2016.
314. An J., Ren S., Murphy S.J., Yan J., Sun Y., Huang Correspondence H., et al. Truncated ERG oncoproteins from TMPRSS2-ERG fusions are resistant to SPOP-mediated proteasome degradation. Mol. Cell 2015, 59:1-13. (Internet. (Available from: http://dx.doi.org/10.1016/j.molcel.2015.07.025.
315. Gan W., Dai X., Lunardi A., Huang J., Pandolfi P.P., Correspondence W.W., et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 2015, 59:1-14. (Internet. (Available from: http://dx.doi.org/10.1016/j.molcel.2015.07.026.
316. Boysen G., Barbieri C.E., Prandi D., Blattner M., Chae S.-S., Dahija A., et al. SPOP mutation leads to genomic instability in prostate cancer. Elife 2015.
317. Ross-Adams H., Lamb A.D., Dunning M.J., Halim S., Lindberg J., Massie C.M., et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. EBioMedicine 2015.
318. Lapointe J., Li C., Higgins J.P., Van De Rijn M., Bair E., Montgomery K., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PNAS 2004, 20;101(3:811-816.
319. Network T.C.G.A.R. The molecular taxonomy of primary prostate cancer. Cell 2015, 163:1011-1025.
320. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 36610366(10:883-892.
321. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467(7319:1114-1117.
322. Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Investig. 2013, 123(11. 4918, (Internet. (Available from: http://www.jci.org.
323. Hong M.K.H., Macintyre G., Wedge D.C., Van Loo P., Patel K., Lunke S., et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 2015, 6.
324. Cunha G.R. The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice'. Anat. Rec. 1973, 175(1:87-96.
325. Risbridger G.P., Almahbobi G.A., Taylor R.A. Early prostate development and its association with late-life prostate disease. Cell Tissue Res. 2005, 322:173-181.
326. Huggins C., Stevens R.E., Hodges C.V. The effects of castration on advanced carcinoma of the prostate gland. JAMA Surg. 1941, 43(2:209-223.
327. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., et al. Induced chromosomal proximity and the genesis of gene fusions in prostate cancer. Science (80 2009, 27;326(5957:1230.
328. Lin C., Yang L., Tanasa B., Hutt K., Ju B.-G., Ohgi K., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 11(1396:1069-1083. December.
329. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., et al. Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42(8:668-675.
330. Mounir Z., Lin F., Lin V., Korn J., Yu Y., Valdez R., et al. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation 2014.
331. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinänen R., Palmberg C., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9(4:401-406.
332. Culig Z., Hobisch A., Cronauer M.V., AC Cato, Hittmair A., Radmayr C., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993, 7(12:1541-1550.
333. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68(13:5469-5477.
334. An J., Wang C., Deng Y., Yu L., Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014, 6:657-669. (Internet. (Available from: http://dx.doi.org/10.1016/j.celrep.2014.01.013.
335. Xu K., Shimelis H., Linn D.E., Jiang R., Yang X., Sun F., et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 2009, 15(4:270-282. (Internet. Elsevier Ltd. (Available from: http://dx.doi.org/10.1016/j.ccr.2009.02.021.
336. Heer R., Robson C.N., Shenton B.K., Leung H.Y. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J. Cell. Physiol. 2007, 212(3:572-578. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/17541959.
337. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5:646-674. (Internet. Elsevier. (Available from: http://www.cell.com/article/S0092867411001279/fulltext.
338. Karanika S., Karantanos T., Li L., Corn P.G., Thompson T.C. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 2014, (February:1-8. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25132269.
339. Pritchard C.C., Morrissey C., Kumar A., Zhang X., Smith C., Coleman I., et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun. 2014, 5.
340. Leongamornlert D., Mahmud N., Tymrakiewicz M., Saunders E., Dadaev T., Castro E., et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 2012, 106. (Internet. (Available from: www.bjcancer.com.
341. Van Asperen C.J., Brohet R.M., Meijers-Heijboer E.J., Hoogerbrugge N., Verhoef S., Vasen H.F.A., et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 2005, 42:711-719.
342. Dong X., Wang L., Taniguchi K., Wang X., Cunningham J.M., McDonnell S.K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 2003, 72(2:270-280.
343. Park J., Huang Y., Sellers T.A. Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk. Methods Mol. Biol. 2009, 471:361-385.
344. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, Macdonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Available from: doi:10.1016/j.eururo.2012.08.053.
345. Yoshimoto M., Ding K., Sweet J.M., Ludkovski O., Trottier G., Song K.S., et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod. Pathol. 2012, 26(10:435-447.
346. Karantanos T., Corn P.G., Thompson T.C. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013, 32(49:5501-5511. (Internet. Macmillan Publishers Limited. (Available from: http://dx.doi.org/10.1038/onc.2013.206.
347. Schiewer M.J., Goodwin J.F., Han S., Chad Brenner J., Augello M.a, Dean J.L., et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012, 2(12:1134-1149.
348. Goodwin J.F., Schiewer M.J., Dean J.L., Schrecengost R.S., de Leeuw R., Han S., et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013, 3(11:1254-1271. (Internet. American Association for Cancer Research. (Available from: http://cancerdiscovery.aacrjournals.org/content/3/11/1254.full.
349. Luedeke M., Linnert C.M., Hofer M.D., Surowy H.M., Rinckleb A.E., Hoegel J., et al. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol. Biomark. Prev. 2009, 18(11:3030-3035.
350. Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B., Farrar W.L. CD44+ CD24(- prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98(4:756-765.
351. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer Stem Cells: Mirage or Reality? 2009.
352. Ting D.T., Wittner B.S., Ligorio M., Vincent Jordan N., Shah A.M., Miyamoto D.T., et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014, 8(6:1905-1918. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/25242334.
353. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.-M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006, 66(17:8337-8341. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/16951139.
354. Gao D., Vela I., Sboner A., Iaquinta P.J., Karthaus W.R., Gopalan A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159:176-187. (Internet. (Available from: http://dx.doi.org/10.1016/j.cell.2014.08.016.
355. Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999, 39(2:135-148.
356. Hansel D.E., Nakayama M., Luo J., Abukhdeir A.M., Park B.H., Bieberich C.J., et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 2009, 69(6:603-609. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3170854&tool=pmcentrez&rendertype=abstract.
357. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., Macdonald T.Y., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets 2011, Vol. 1(6:487-495.
358. Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch a, Hittmair a, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer 1999, 81:242-251.
359. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. PNAS 2001, 24;98(9:4904-4909.
360. Haapala K., Hyytinen E.R., Roiha M., Laurila M., Rantala I., Helin H.J., et al. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab. Investig. 2001, 81(12:1647-1651. (Internet. (Available from: http://www.ncbi.nlm.nih.gov/pubmed/11742035.
361. Suzuki H., Ueda T., Ichikawa T., Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003, 10(2:209-216.
362. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995, 332(21:1393-1398.
363. Joseph J.D., Lu N., Qian J., Sensintaffar J., Shao G., Brigham D., et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013, 3(9:1020-1029.
364. Korpal M., Korn J.M., Gao X., Rakiec D.P., Ruddy D., Doshi S., et al. An F876l mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide. Cancer Discov. 2013, 3(9:1030-1043.
365. Hovelson D.H., McDaniel A.S., Cani A.K., Johnson B., Rhodes K., Williams P.D., et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia 2015, 17(4:385-399.
366. Zhang L., Altuwaijri S., Deng F., Chen L., Lal P., Bhanot U.K., et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am. J. Pathol. 2009, 175(2:489-499. (Internet. American Society for Investigative Pathology. (Available from: http://dx.doi.org/10.2353/ajpath.2009.080727.
367. Sharma A., Yeow W.-S., Ertel A., Coleman I., Clegg N., Thangavel C., et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 2010, 120(12:4478-4492. (Internet. American Society for Clinical Investigation. (Available from: http://www.jci.org/articles/view/44239.
368. Carreira S., Romanel A., Goodall J., Grist E., Ferraldeschi R., Miranda S., et al. Tumor clone dynamics in lethal prostate cancer HHS Public Access. Sci. Transl. Med. Sept. 2014, 17(6254. art. no. 254ra125. (Internet. (Available from: www.sciencetranslationalmedicine.org/cgi/content/full/6/254/254ra125/DC1.
369. Gundem G., Van Loo P., Kremeyer B., Alexandrov L.B., Tubio J.M.C., Papaemmanuil E., et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520(7547:353-357. (Internet. (Available from: http://www.nature.com/doifinder/10.1038/nature14347/nhttp://dx.doi.org/10.1038/nature14347.
370. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999, 59(4:803-806.
371. Tepper C.G., Boucher D.L., Ryan P.E., Ma A.-H., Xia L., Lee L.-F., et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res. 2002, 62(22:6606-6614.
372. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69(6:2305-2313.
373. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69(1:16-22. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2614301&tool=pmcentrez&rendertype=abstract.
374. Li Y., Chan S.C., Brand L.J., Hwang T.H., Silverstein K., SM Dehm Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013, 73(2:483-489.
375. Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014, 371(11:1028-1038. (Internet. (Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4201502&tool=pmcentrez&rendertype=abstract.
376. Deng Q., Tang D.G. Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr. Relat. Cancer. 2015, 22(6:T209-220.
377. Menon R., Deng M., Rüenauver K., Queisser A., Pfeifer M., Offermann A., et al. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer. J. Pathol. 2013, 231:505-516.
378. Rajan P., Sudbery I.M., Eugenia M., Villasevil M., Mui E., Fleming J., et al. Platinum priority - prostate cancer next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur. Urol. 2014, 66(2:32-39. (Internet. (Available from: http://dx.doi.org/10.1016/j.eururo.2013.08.011.
379. Kelly K., Yin J.J. Prostate cancer and metastasis initiating stem cells. Cell Res. 2008, 18(5:528-537.
380. Li H., Tang D.G. Prostate cancer stem cells and their potential roles in metastasis. J. Surg. Oncol. 2011, 103(6:558-562. (Internet. (Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=21480250&retmode=ref&cmd=prlinks/npapers2://publication/doi/10.1002/jso.21806.
381. Rane J.K., Scaravilli M., Ylipää A., Pellacani D., Mann V.M., Simms M.S., et al. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur. Urol. 2015, 67:7-10.
382. Smith B.A., Sokolov A., Uzunangelov V., Baertsch R., Newton Y., Graim K., et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. PNAS 2015, 24;112(47:E6544-6552.